On July 17, 2026 SL Science Holding Limited (NASDAQ: SLBT) ("SL Science" or "we"), a biotechnology company developing next-generation immune cell therapies, reported our successful exhibition and participation at the 2026 World Congress of Basic and Clinical Pharmacology (WCP 2026) held July 12–17, 2026 in Melbourne, Australia. Together with our esteemed academic and industry partners, we presented highly promising preclinical research on a novel treatment for glioblastoma (GBM), one of the most aggressive and difficult-to-treat forms of brain cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The research showcased at the WCP 2026 exhibition is the result of a robust joint effort led by investigators at Taipei Medical University, in collaboration with SL Science, JY Biomedical Co., Ltd. ("JY BioMed") and HeXun Biosciences Co., Ltd.
Simplifying Complex Science for Real-World Impact
Glioblastoma is notoriously challenging to treat, often resisting conventional therapies such as surgery, radiation, and chemotherapy. Because tumors frequently return and build resistance, there is an urgent global need for innovative solutions. Our exhibition focused on harnessing gamma delta (γδ) T cells—a specialized subset of immune cells capable of identifying and attacking cancer cells without relying on the standard immune-matching processes that other therapies require.
The exhibited data revealed significant progress in overcoming tumor immune evasion. By delivering these specially expanded γδ T cells directly to the tumor site in preclinical models, researchers observed potent and efficient destruction of the brain cancer cells.
Key Exhibition Highlights
Complete Tumor Elimination: Direct administration of γδ T cells achieved complete eradication of the tumor by day 26 post-treatment at the highest dose tested (an 8:1 ratio of immune cells to cancer cells).
Dose-Dependent Success: The research demonstrated the feasibility and effectiveness of repeated direct-to-brain dosing, showing that the tumor-suppressing benefits scaled positively with the dosage.
Clean Safety Profile: Comprehensive health screens and blood panels confirmed that the treatment was well-tolerated in the study, showing no major safety concerns or adverse health effects.
"Exhibiting our collaborative work at WCP 2026 was a monumental milestone for our entire team and our partners," said Mr. William Wang, Chairman and Chief Executive Officer of SL Science. "We were thrilled to present these findings on a global stage. This research underscores the tremendous therapeutic potential of our γδ T-cell platform to combat challenging solid tumors like glioblastoma. By working closely with leading academic institutions, we are translating complex biology into tangible hope for patients facing high unmet medical needs."
(Press release, SL Science, JUL 17, 2026, View Source [SID1234669318])